

**INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION
(ISHLT)**

**BASIC SCIENCE & TRANSLATIONAL RESEARCH
CORE COMPETENCY CURRICULUM
(ISHLT BSTR CCC)**

SECOND EDITION

THE EDUCATIONAL WORKFORCE OF THE
ISHLT BASIC SCIENCE & TRANSLATIONAL RESEARCH COUNCIL

T. MARTINU, E. DIJKE, S. VERLEDEN

CONTACTS:

TEREZA MARTINU

EMAIL: TEREZA.MARTINU@UHN.CA

PHONE: 416.340.4800

FAX: 416.340.3350

ESMÉ DIJKE

EMAIL: DIJKE@UALBERTA.CA

PHONE: 780.492.7259

FAX: 780.492.8239

(V1.1 NOVEMBER 2018)

ISHLT BASIC SCIENCE & TRANSLATIONAL RESEARCH COUNCIL

EDUCATIONAL WORKFORCE

WORKFORCE LEADERS

ESMÉ DIJKE, PHD

UNIVERSITY OF ALBERTA
DEPARTMENT OF LAB MEDICINE & PATHOLOGY
WALTER C. MACKENZIE HEALTH SCIENCES CENTER
8440-112 STREET, ROOM 4B4.19
EDMONTON, ALBERTA T6G 2B7
DIJKE@UALBERTA.CA

TEREZA MARTINU, MD

DUKE UNIVERSITY MEDICAL CENTER
BUILDING MSRB2, SUITE 2073-2, DUMC Box 103000
106 RESEARCH DRIVE
DURHAM, NC 27710
TEREZA.MARTINU@DUKE.EDU

STIJN VERLEDEN, PHD

LAB OF LUNG TRANSPLANTATION
DEPARTMENT OF PNEUMOLOGY
BOX 706, HERESTRAAT 49, 3000
LEUVEN
STIJN.VERLEDEN@KULEUVEN.BE

PRIOR CONTRIBUTORS:

SONJA SCHREPFER, MD PHD, STANFORD, CA
CARLA BAAN, PHD, ROTTERDAM, THE NETHERLANDS
MARILIA CASCALHO, MD PHD, ANN ARBOR, MI
KIM GANDY, MD, PHD, KANSAS CITY, MO
DANIEL CHAMBERS, MBBS, MD, BRISBANE, AUSTRALIA
RICHARD KIRK, MA FRCP FRCPCH, NEWCASTLE, UK

ISHLT BSTR CCC: LIST OF CONTENTS

	PAGE
I. INTRODUCTION AND OVERALL GOALS	3
Educational Goals	
Learning Objectives	
II. BASIC IMMUNOLOGY	4
Learning Objectives	
1. Innate immunity	
2. Adaptive immunity	
Selected References and Hyperlinks	
III. TRANSPLANT IMMUNOBIOLOGY	7
Learning Objectives	
1. Ischemia reperfusion injury	
2. Immune reactivity to alloantigens	
3. Immune regulation of alloantigen response	
4. Immunity against infectious agents	
5. Microbiome and its interaction with the immune system	
Selected References and Hyperlinks	
IV. IMMUNOSUPPRESSION AND IMMUNOMODULATION	12
Learning Objectives	
1. Overview of immunosuppressive agents and their mode of action	
2. Systemic mechanical immunosuppression	
3. Cellular therapy	
Selected References and Hyperlinks	
V. RESEARCH MODELS, ASSAYS, AND TECHNOLOGIES	16
Learning Objectives	
1. Pre-clinical models	
2. Samples for translational and clinical science	
3. Key analytical techniques	
4. Novel technologies for improved diagnostics	
Selected References and Hyperlinks	

I. INTRODUCTION AND OVERALL GOALS

The purpose of this compendium is to provide a Core Competency Curriculum in Basic Science and Translational Research (BSTR) as it relates to heart and lung failure and transplantation. This curriculum does not replace a textbook, but intends to provide an outline of essential topics in the field of BSTR as well as references and hyperlinks that should be considered for individual study to develop competencies in various aspects of BSTR. The ISHLT BSTR Academy will focus on core competencies in Basic Science and Translational Research and will fill gaps in practice by assisting clinicians in improving their understanding of the scientific background behind clinical practice, updating basic and translational researchers on recent discoveries, encouraging interaction between basic/translational researchers and clinicians, and stimulating discussion about common basic topics in the fields of heart versus lung failure and transplantation. The Educational Workforce of the ISHLT BSTR Council recognizes the role of BSTR in every discipline of the ISHLT and acknowledges the challenges of accommodating all disciplines in this BSTR Core Competency Curriculum. This compendium and the ISHLT BSTR Academy will therefore focus on basic concepts in immunology and molecular biology related to heart and lung transplantation. Future developments and addendums of this Curriculum may integrate other disciplines. We welcome constructive feedback to further develop the scope and accuracy.

Educational Goals

The educational goals of this activity are to provide a concise review of basic concepts in transplant-related immunology and molecular biology, to define and promote the clinical relevance of BSTR related to heart and lung transplantation, and to encourage interaction between basic scientists, translational researchers, and clinicians via a networking opportunity.

Learning Objectives

After completing this curriculum, participants will have improved competency and professional performance in their abilities to:

1. Understand basic concepts in transplant-related immunology and molecular biology;
2. Recognize key analytical techniques and models used in transplantation research;
3. Understand basic mechanisms of immunosuppression;
4. Recognize key contributions from basic research in transplantation that improved clinical outcomes in heart and lung transplantation;
5. Recognize how clinical questions may inspire basic research;
6. Enable effective communication between research scientists and clinicians and health care professionals.

II. BASIC IMMUNOLOGY

Learning Objectives for Basic Immunology:

- 1) Understand the principles of inflammation and the role of the complement system;
- 2) Describe the cells of the innate and adaptive immune system and their mode of action;
- 3) Distinguish between properties of innate immunity and adaptive immunity;
- 4) Understand how immune cells recognize antigens;
- 5) Understand the processes of cell-cell interaction and activation;
- 6) Describe the immunoregulatory mechanisms for the control of (self-)reactive cells;
- 7) Understand the concept of immunologic memory.

1. Innate immunity

- A. Inflammation
- B. Complement system
- C. Innate immunity cells
 - i. Macrophages
 - ii. Dendritic cells
 - iii. Natural killer cells
 - iv. Neutrophils
 - v. Mast cells
- D. Toll-like receptors (TLR)
 - i. Diversity
 - ii. Ligands
 - iii. Signalling

2. Adaptive immunity

- A. Adaptive immunity cells
 - i. T cells
 - ii. B cells
 - iii. NKT cells
- B. Cell-cell interaction
 - i. Co-stimulation
 - ii. Cytokines/chemokines
- C. Antigen recognition
 - i. T cells
 - a. T cell receptor
 - b. Major histocompatibility complex (MHC)

- ii. B cells
 - a. B cell receptor
 - b. Antibodies
- iii. NKT cell
 - a. CD1d molecule
- D. Cell activation/signalling
- E. Cell regulation
 - i. Anergy
 - ii. Deletion
 - iii. Ignorance
 - iv. Active suppression
- F. Naïve versus memory
- G. Cell death
 - i. Programmed cell death/apoptosis
 - ii. Necrosis

Selected References:

Textbooks

- Sompayrac LM. **How the immune system works**. 4th edition, 2012. Wiley-Blackwell. ISBN-10: 0470657294, ISBN-13: 978-0470657294.
- Abbas AK et al. **Basic Immunology**. 4th edition, 2014. Elsevier Health Sciences. ISBN-10: 1455707074, ISBN-13: 9781455707072.
- Murphy KM. **Janeway's Immunobiology**. 8th edition, 2011. Garland science. ISBN-10: 0815342438, ISBN-13: 978-0815342434.

Journal Articles

- Chen GY et al. **Sterile inflammation: sensing and reacting to damage**. Nat Rev Immunol, 2012. 10: 826.
- Shen H et al. **Processes of sterile inflammation**. J Immunol, 2013. 191: 2857.
- Sarma JV et al. **The complement system**. Cell Tissue Res, 2011. 343: 227.
- Janeway CA Jr. et al. **Innate immune recognition**. Annu Rev Immunol, 2002. 20: 197.
- Iwasaki A et al. **Regulation of adaptive immunity by the innate immune system**. Science, 2010. 327: 291.
- Dempsey PW et al. **The art of war: Innate and adaptive immune responses**. Cell Mol Life Sci, 2003. 60: 2604.
- Chen L et al. **Molecular mechanisms of T cell co-stimulation and co-inhibition**. Nat Rev Immunol, 2013. 13: 227.
- O'Shea JJ et al. **Cytokine signaling modules in inflammatory responses**. Immunity, 2008. 28: 477.
- Tisoncik JR et al. **Into the eye of the cytokine storm**. Microbiol Mol Biol Rev, 2012. 76: 16.
- Locati M et al. **Chemokines and their receptors: roles in specific clinical conditions and measurement in the clinical laboratory**. Am J Clin Pathol, 2005. 123 Suppl: p. S82.
- Huppa JB et al. **T-cell-antigen recognition and the immunological synapse**. Nat Rev Immunol, 2003. 3: 973.
- Regner M. **Cross-reactivity in T-cell antigen recognition**. Immunol Cell Biol, 2001. 79: 91.
- von Essen MR et al. **Mechanisms behind functional avidity maturation in T cells**. Clin Dev Immunol, 2012. 2012: 163453.

- Batista FD et al. **The who, how and where of antigen presentation to B cells.** Nat Rev Immunol, 2009. 9: 15.
- Bendelac A et al. **The biology of NKT cells.** Annu Rev Immunol, 2007. 25: 297.
- Mueller DL. **Mechanisms maintaining peripheral tolerance.** Nat Immunol, 2010. 11: 21.
- Mellor AL et al. **Creating immune privilege: active local suppression that benefits friends, but protects foes.** Nat Rev Immunol, 2008. 8: 74.
- Vignali DA et al. **How regulatory T cells work.** Nat Rev Immunol, 2008. 8: 523.
- Manjarrez-Orduno N et al. **B cells and immunological tolerance.** J Invest Dermatol, 2009. 129: 278.
- Gourley TS et al. **Generation and maintenance of immunological memory.** Semin Immunol, 2004. 16: 323.
- Kaech SM et al. **Effector and memory T-cell differentiation: implications for vaccine development.** Nat Rev Immunol, 2002. 2: 251.
- Fink SL et al. **Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells.** Infect Immun, 2005. 73: 1907.

Selected Hyperlinks:

Posters

- **Innate immunity:** http://www.nature.com/nri/posters/innate/nri0804_ii_poster.pdf
- **Dendritic cells:** http://www.nature.com/nri/posters/dendriticcells/nri1107_dendriticcells_poster.pdf
- **NK cells:** http://www.nature.com/nri/posters/nkcells/nri1012_nkcells_poster.pdf
- **T cell subsets:** http://www.nature.com/nri/posters/tcellsubsets/nri1009_tcellsubsets_poster.pdf
- **B cell subsets:** <http://www.docstoc.com/docs/113396676/b-cell-poster>
- **Antigen processing:** http://www.nature.com/nri/posters/antigenprocessing/nri0905_antigen_poster.pdf

Videos

- **Complement system:** <http://www.youtube.com/watch?v=vbWYz9XDtLw>
- **Innate pathogen recognition:** <http://www.youtube.com/watch?v=gRKHeDzfh0Y&list=PL7D18C93964A61F67>
- **MHC class I processing:** <http://www.youtube.com/watch?v=vrFMWyJwGxw&list=PL7D18C93964A61F67>
- **MHC class II processing:** <http://www.youtube.com/watch?v=8JMVq7HF2Y&list=PL7D18C93964A61F67>
- **TCR-APC interaction:** http://www.youtube.com/watch?v=Xt_y7f6Kivl&list=PL7D18C93964A61F67
- **Immunological synapse:** <http://www.youtube.com/watch?v=R4zuWO5krAw&list=PL7D18C93964A61F67>
- **Monoclonal and polyclonal antibodies:** <http://www.youtube.com/watch?v=I-QSlwyUly8>
- **Necrosis versus apoptosis:** http://www.youtube.com/watch?v=4wPlw_Bdz7Q

III. TRANSPLANT IMMUNOBIOLOGY

Learning Objectives for Transplant Immunology:

- 1) Define the mechanisms behind ischemia reperfusion injury;
- 2) Understand the concept of allorecognition;
- 3) Define the mechanistic differences and interactions between cellular and humoral, acute and chronic, rejection;
- 4) Recognize the basis for current controversies in the diagnosis and treatment of antibody-mediated rejection;
- 5) Describe major mechanisms of immunologic regulation and tolerance in transplantation.

1. Ischemia reperfusion injury

A. Mechanisms

2. Immune reactivity to alloantigens

A. Alloantigens

- i. ABO blood group system
- ii. HLA antigens and HLA antigen nomenclature
- iii. Non-HLA antigens

B. Mechanisms of allorecognition

- i. Direct
- ii. Indirect
- iii. Semi-direct
- iv. Role of intra-graft T cell activation and tertiary lymphoid organs

C. Antibody-mediated versus cellular rejection

- i. Critical concepts and controversies in detection and treatment of antibody-mediated and cellular rejection
- ii. Mechanisms of T cell-based rejection
- iii. Mechanisms of B cell-based / antibody-mediated rejection
- iv. Anti-HLA antibodies in rejection
 - ii. HLA antibody nomenclature
 - iii. HLA mismatch
 - iv. Eplet/epitope mismatch
- i. Auto-antibodies in rejection

B. Type of allograft rejection

- i. Hyperacute rejection
- ii. Acute rejection
- iii. Chronic rejection
 - a. Bronchiolitis obliterans syndrome (BOS) in lung transplantation and epithelial injury
 - b. Chronic allograft vasculopathy (CAV) in heart transplantation and endothelial injury
 - c. Fibrosis pathways

3. Immune regulation of alloantigen response

A. Mechanisms of immune regulation

- i. Deletion
- ii. Active suppression by regulatory cells
 - a. Regulatory T cells
 - b. Regulatory B cells
 - c. Regulatory macrophages
 - d. Tolerogenic dendritic cells
 - e. Myeloid-derived suppressor cells
 - f. Stem cells
 - g. NK cells

B. Definition of tolerance

C. Definition and possible mechanisms of accommodation

4. Immunity against infectious agents

A. Host-defense during post-transplant infections

- i. Colonization versus infection
- ii. Bacterial (e.g. Pseudomonas)
- iii. Mycobacterial
- iv. Fungal (e.g. Aspergillus)
- v. Viral
 - a. Latent (e.g. CMV, HSV)
 - b. Community acquired respiratory viruses

B. Effect of infections on alloreactivity, rejection, and outcomes

5. Microbiome and its interaction with the immune system

A. Bacterial microbiome

B. Virome

C. Fungome

Selected References:

Journal Articles

- Weyker PD et al. **Lung ischemia reperfusion injury: a bench-to-bedside review.** *Sem Cardio Vasc Anesth*, 2012. 17: 28.
- Den Hengst WA et al. **Lung ischemia-reperfusion injury: a molecular and clinical view on a complex pathophysiological process.** *Am J Physiol Heart Circ Physiol*, 2010. 299: H1283.
- Frohlich GM et al. **Myocardial reperfusion injury: looking beyond primary PCI.** *Eur Heart J*, 2013. 32: 1714.
- Yamani MH et al. **Myocardial ischemic injury after heart transplantation is associated with upregulation of vitronectin receptor (integrin alpha(v)beta3), activation of matrix metalloproteinase induction system, and subsequent development of coronary vasculopathy.** *Circulation*, 2002. 105: 1955.
- Kreisel D et al. **Innate immunity and organ transplantation: focus on lung transplantation.** *Transpl Int*, 2013. 26: 2.
- Paantjens AW et al. **Chimerism of dendritic cell subsets in peripheral blood after lung transplantation.** *J Heart Lung Transplant*, 2011. 30: 691.
- Millington TM et al. **Innate immunity and cardiac allograft rejection.** *Kidney Int Suppl*, 2010. 119: S18.
- Heeger PS et al. **Transplant immunology for non-immunologist.** *Mt Sinai J Med*, 2012. 79: 376.
- Felix NJ et al. **Specificity of T-cell alloreactivity.** *Nat Rev Immunol*, 2007. 7: 942.
- Valujskikh et al. **Recent progress and new perspectives in studying T cell responses to allografts.** *Am J Transplant*, 2010. 10: 1117.
- Csencsits KL et al. **Contrasting alloreactive CD4+ and CD8+ T cells: there's more to it than MHC restriction.** *Am J Transplant*, 2003. 3: 107.
- D'Orsogna LJ et al. **TCR cross-reactivity and allorecognition: new insights into the immunogenetics of allorecognition.** *Immunogenetics*, 2012. 64: 77.
- Le Moine A et al. **A brief focus on memory cells in transplantation.** *Transplantation Proceedings*, 2009. 41: 3361.
- Chadha R et al. **Th17: contributors to allograft rejection and a barrier to the induction of transplantation tolerance?** *Transplantation*, 2011. 91: 939.
- Coelho V et al. **Rethinking the multiple roles of B cells in organ transplantation.** *Curr Opin Organ Transplant*, 2013. 18: 13.
- Martinu et al. **Acute rejection and humoral sensitization in lung transplant recipients.** *Proc Am Thorac Soc*, 2009. 6: 54.
- McManigle W et al. **Acute cellular and antibody-mediated allograft rejection.** *Semin Respir Crit Care Med*, 2013. 34: 320.
- Shilling RA et al. **Immunobiology of chronic lung allograft dysfunction: new insights from the bench and beyond.** *Am J Transplant*, 2009. 9: 1714.
- Belperio JA et al. **Chronic lung allograft rejection: mechanisms and therapy.** *Proc Am Thorac Soc*, 2009. 6: 108.
- Gelman AE et al. **CD4+ T lymphocytes are not necessary for the acute rejection of vascularized mouse lung transplants.** *J Immunol*, 2008. 180: 4754.
- Gelman AE et al. **Cutting edge: Acute lung allograft rejection is independent of secondary lymphoid organs.** *J Immunol*, 2009. 182: 3969.
- Sato M et al. **The role of intrapulmonary de novo lymphoid tissue in obliterative bronchiolitis after lung transplantation.** *J Immunol*, 2009. 182: 7307.
- Fan L et al. **Neutralizing IL-17 prevents obliterative bronchiolitis in murine orthotopic lung transplantation.** *Am J Transplant*, 2011. 11: 911.
- Higuchi T et al. **Different kinetics of obliterative airway disease development in heterotopic murine tracheal allografts induced by CD4+ and CD8+ T cells.** *Transplantation*, 2002. 74: 646.
- King MB et al. **Obliterative airway disease progresses in heterotopic airway allografts without persistent alloimmune stimulus.** *Transplantation*, 2002. 74: 557.
- Okazaki M et al. **Maintenance of airway epithelium in acutely rejected orthotopic vascularized mouse lung transplants.** *Am J Respir Cell Mol Biol*, 2007. 37: 625.
- VanBuskirk AM et al. **Transfusion of polarized TH2-like cell populations into SCID mouse cardiac allograft recipients results in acute allograft rejection.** *Transplantation*, 1996. 62: 229.

- Lakkis FG et al. **Immunologic ignorance of vascularized organ transplants in the absence of secondary lymphoid tissue**. Nat Med, 2000. 6: 686.
- Savasta M et al. **Immunology insights into cardiac allograft rejection**. Rev Cardiovasc Med, 2011. 12: e68.
- Weiss MJ et al. **Mechanisms of chronic rejection in cardiothoracic transplantation**. Front Biosci, 2008. 13: 2980.
- Soleimani B et al. **Role of antibodies in the pathogenesis of graft arteriosclerosis in cardiac transplantation**. Am J Transplant, 2006. 6: 1781.
- Issa F et al. **The where and when of T cell regulation in transplantation**. Trends Immunol, 2013. 34: 107.
- Krupnick AS et al. **Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells**. J Immunol, 2005. 175: 6265.
- Bharat A et al. **CD4+25+ regulatory T cells limit Th1-autoimmunity by inducing IL-10 producing T cells following human lung transplantation**. Am J Transplant, 2006. 6: 1799.
- Yamamoto et al. **Pseudomonas aeruginosa abolishes established lung transplant tolerance by stimulating B7 expression on neutrophils**. J Immunol, 2012. 189: 4221.
- Dorling A. **Transplant accommodation – are the lessons learned from xenotransplantation pertinent for clinical allotransplantation?** Am J Transplant, 2012. 12: 545.
- Lynch RJ et al. **Accommodation in renal transplantation: unanswered questions**. Curr Opin Organ Transplant, 2010. 15: 481.
- West LJ. **Targeting antibody-mediated rejection in the setting of ABO-incompatible infant heart transplantation: graft accommodation vs. B cell tolerance**. Curr Drug Targets Cardiovasc Haematol Disord, 2005. 5: 223.
- Weigt SS, Wang X, Palchevskiy V, Patel N, Derhovanessian A, Shino MY, Sayah DM, Lynch JP 3rd, Saggarr R, Ross DJ, Kubak BM, Ardehali A, Palmer S, Husain S, Belperio JA. [Gene Expression Profiling of Bronchoalveolar Lavage Cells During Aspergillus Colonization of the Lung Allograft](#). Transplantation. 2018 Jun;102(6):986-993.
- Kabbani D, Bhaskaran A, Singer LG, Bhimji A, Rotstein C, Keshavjee S, Liles WC, Husain S. [Pentraxin 3 levels in bronchoalveolar lavage fluid of lung transplant recipients with invasive aspergillosis](#). J Heart Lung Transplant. 2017 Sep;36(9):973-979
- Sullivan LC, Westall GP, Widjaja JM, Mifsud NA, Nguyen TH, Meehan AC, Kotsimbos TC, Brooks AG. [The Presence of HLA-E-Restricted, CMV-Specific CD8+ T Cells in the Blood of Lung Transplant Recipients Correlates with Chronic Allograft Rejection](#). PLoS One. 2015 Aug 24;10(8):e0135972.
- Borthwick LA, Suwara MI, Carnell SC, Green NJ, Mahida R, Dixon D, Gillespie CS, Cartwright TN, Horabin J, Walker A, Olin E, Rangar M, Gardner A, Mann J, Corris PA, Mann DA, Fisher AJ. [Pseudomonas aeruginosa Induced Airway Epithelial Injury Drives Fibroblast Activation: A Mechanism in Chronic Lung Allograft Dysfunction](#). Am J Transplant. 2016 Jun;16(6):1751-65
- Borthwick LA, Sunny SS, Oliphant V, Perry J, Brodrie M, Johnson GE, Ward C, Gould K, Corris PA, De Soyza A, Fisher AJ. [Pseudomonas aeruginosa accentuates epithelial-to-mesenchymal transition in the airway](#). Eur Respir J. 2011 May;37(5):1237-47.
- Mitchell AB, Mourad B, Morgan LC, Oliver BGG, Glanville AR. [Transplanting the pulmonary virome: Dynamics of transient populations](#). J Heart Lung Transplant. 2018 Sep;37(9):1111-1118.
- Schott C, Weigt SS, Turturice BA, Metwally A, Belperio J, Finn PW, Perkins DL. [Bronchiolitis obliterans syndrome susceptibility and the pulmonary microbiome](#). J Heart Lung Transplant. 2018 Sep;37(9):1131-1140.
- O'Dwyer DN, Zhou X, Wilke CA, Xia M, Falkowski NR, Norman KC, Arnold KB, Huffnagle GB, Murray S, Erb-Downward JR, Yanik GA, Moore BB, Dickson RP. [Lung Dysbiosis, Inflammation, and Injury in Hematopoietic Cell Transplantation](#). Am J Respir Crit Care Med. 2018 Jun 7
- Mouraux S, Bernasconi E, Pattaroni C, Koutsokera A, Aubert JD, Claustre J, Pison C, Royer PJ, Magnan A, Kessler R, Benden C, Soccac PM, Marsland BJ, Nicod LP; SysCLAD Consortium. [Airway microbiota signals anabolic and catabolic remodeling in the transplanted lung](#). J Allergy Clin Immunol. 2018 Feb;141(2):718-729.
- Bernasconi E, Pattaroni C, Koutsokera A, Pison C, Kessler R, Benden C, Soccac PM, Magnan A, Aubert JD, Marsland BJ, Nicod LP; SysCLAD Consortium. [Airway Microbiota Determines Innate Cell Inflammatory or Tissue Remodeling Profiles in Lung Transplantation](#). Am J Respir Crit Care Med. 2016 Nov 15;194(10):1252-1263

- Willner DL, Hugenholtz P, Yerkovich ST, Tan ME, Daly JN, Lachner N, Hopkins PM, Chambers DC. **Reestablishment of recipient-associated microbiota in the lung allograft is linked to reduced risk of bronchiolitis obliterans syndrome.** Am J Respir Crit Care Med. 2013 Mar 15;187(6):640-7.
- Calabrese DR, Lanier LL, Greenland JR. [Natural killer cells in lung transplantation.](#) Thorax. 2018

Selected Hyperlinks:

Posters

- **Regulatory T cells:** <http://www.nature.com/nri/posters/tregcells/index.html>
- **Myeloid-derived suppressor cells:** http://www.nature.com/nri/posters/mdscs/nri1005_mdscs_poster.pdf

Videos

- **Transplant immunology and rejection: Fundamentals.** <https://www.youtube.com/watch?v=F9UWVSZ0E4g>
- **Memory cells and rejection: Improving transplant results.** By Dr. Alan Kirk at Emory. <https://www.youtube.com/watch?v=Ut5Q4XnZtnE>

IV. IMMUNOSUPPRESSION AND IMMUNOMODULATION

Learning Objectives for Immunosuppression:

- 1) Review the history of immunosuppression in heart and lung transplantation;
- 2) Recognize major categories of immunosuppressive agents used in heart and lung transplantation;
- 3) Describe the mode of action of immunosuppressive agents;
- 4) Discuss novel targets in immunosuppression and novel pathways and drugs in the pipeline;
- 5) Understand the principle of cell-based strategies to induce transplant tolerance.

1. Overview of immunosuppressive agents and their mode of action

A. Current immunosuppressive agents

- i. Calcineurin inhibitors
- ii. Cell-cycle inhibitors
- iii. Target-of-Rapamycin inhibitors
- iv. Steroid agents
- v. Monoclonal and polyclonal antibodies
- vi. Other agents

B. Novel immunosuppressive agents (in experimental use only)

2. Systemic mechanical immunosuppression

A. Total body irradiation

B. Total lymphoid irradiation

C. Plasmapheresis, immunoabsorption and photopheresis

D. Other

- i. Splenectomy
- ii. Thymectomy
- iii. Non-mainstream techniques

3. Cellular therapy

A. T cells

- i. Regulatory T cells
- ii. Car-T cells

B. Regulatory B cells

C. Regulatory macrophages

D. Tolerogenic dendritic cells

E. Myeloid-derived suppressor cells

F. Stem cells and progenitor cells

- i. Multipotent stem cells
- ii. Pluripotent stem cells
 - a. Embryonic stem cells
 - b. Induced pluripotent stem (iPS) cells
- iii. Progenitor cells

Selected References:

Journal Articles

- Lindenfeld J et al. **Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.** *Circulation*, 2004. 110: 3858.
- Khush KK et al. **New developments in immunosuppressive therapy for heart transplantation.** *Expert Opin Emerg Drugs*, 2009. 14: 1.
- Bhorade SM et al. **Immunosuppression for lung transplantation.** *Proc Am Thorac Soc*, 2009. 6: 47.
- Page AJ et al. **Memory T cell-specific therapeutics in organ transplantation.** *Curr Opin Organ Transplant*, 2009. 14: 643
- Chih S et al. **A survey of current practice for antibody-mediated rejection in heart transplantation.** *Am J Transplant*, 2013. 13: 1069.
- Singh N et al. **Antibody-mediated rejection: treatment alternatives and outcomes.** *Transplant Rev (Orlando)*, 2009. 23: 34.
- Patel et al. **Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.** *J Heart Lung Transplant*, 2011. 30: 1320.
- Hardinger KL et al. **Novel immunosuppressive agents in kidney transplantation.** *World J Transplant*, 2013. 3: 68.
- Marks SD. **New immunosuppressants in pediatric solid organ transplantation.** *Curr Opin Organ Transplant*, 2012. 17: 503.
- Kim EJ et al. **Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection.** *Am J Transplant*, 2014. 14: 59.
- Hua F et al. **Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.** *J Clin Pharmacol*, 2013. 54: 14.
- Poirier N et al. **Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody.** *Am J Transplant*, 2012. 12: 2630.
- Tallaj JA et al. **Total lymphoid irradiation in heart transplantation: long-term efficacy and survival--an 18-year experience.** *Transplantation*, 2011. 92: 1159.
- Diamond DA et al. **Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation.** *Int J Radiat Oncol Biol Phys*, 1998. 41: 795.
- Babic AM. **Extracorporeal photopheresis: Lighting the way to immunomodulation.** *Am J Hematol*, 2008. 83: 589.
- Slovis BS et al. **Photopheresis for chronic rejection of lung allografts.** *N Engl J Med*, 1995. 332: 962.
- Marques MB et al. **Update on extracorporeal photopheresis in heart and lung transplantation.** *J Clin Apher*, 2011. 26: 146.
- Dieterlen MT et al. **Immunological monitoring of extracorporeal photopheresis after heart transplantation.** *Clin Exp Immunol*, 2014. 176: 120.
- Ogle BM et al. **Effacing of the T cell compartment by cardiac transplantation in infancy.** *J Immunol*, 2006. 176: 1962.
- Geissler EK et al. **Cell therapy as a strategy to minimize maintenance immunosuppression in solid organ transplant recipients.** *Curr Opin Organ Transplant*, 2013. 18: 408.
- Ruiz P et al. **Transplant tolerance: new insights and strategies for long-term allograft acceptance.** *Clin Dev Immunol*, 2013. 2013: 210506.
- Ferrer IR et al. **Induction of transplantation tolerance through regulatory cells: from mice to men.** *Immunol Rev*, 2014. 258: 102.
- Tang Q et al. **Regulatory T-cell therapy in transplantation: moving to the clinic.** *Cold Spring Harb Perspect Med*, 2013. 3: 1.
- Safinia N et al. **Promoting transplantation tolerance; adoptive regulatory T cell therapy.** *Clin Exp Immunol*, 2013. 172: 158.
- McMurchy AN et al. **Moving to tolerance: clinical application of T regulatory cells.** *Semin Immunol*, 2011. 23: 304.
- Edozie FC, et al. **Regulatory T-cell therapy in the induction of transplant tolerance: the issue of subpopulations.** *Transplantation*. 2014 98(4): 370-9.
- [Mathew](#) JM et al. **A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants.** *Scientific Reports* 2018.
- Gliwinski M et al. **Cell-Based Therapies with T Regulatory Cells.** *BioDrugs*, 2017. 31: 335.
- MacDonald K et al. **Alloantigen-Specific Regulatory T Cells Generated with a Chimeric Antigen Receptor.** *J Clin Invest*, 2016. 126: 1413.

- McGovern JL et al. **Engineering Specificity and Function of Therapeutic Regulatory T cells.** Front. Immunol, 2017. 8: 1517.
- Sicard A et al. [Engineering therapeutic T cells to suppress alloimmune responses using TCRs, CARs, or BARs.](#) Am J Transplant. 2018 Jun;18(6):1305-1311.
- Sicard A et al **Taking Regulatory T-Cell Therapy One Step Further.** Curr Opin Organ Transplant, 2018. 23: 509. Nouel A et al. **Regulatory B Cells: An Exciting Target for Future Therapeutics in Transplantation.** Front Immunol, 2014. 5: 11.
- Broichhausen C et al. **Regulatory macrophages as therapeutic targets and therapeutic agents in solid organ transplantation.** Curr Opin Organ Transplant, 2012. 17: 332.
- Raich-Regue D et al. **Regulatory dendritic cell therapy: From rodents to clinical application.** Immunol Lett, 2013.
- Rosborough BR et al. **Regulatory myeloid cells in transplantation.** Transplantation, 2014. 97: 367.
- Franquesa M et al. **Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials.** Transplantation, 2013. 96: 234.
- Reinders ME et al. **Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders.** Curr Pharm Des, 2013.
- Casiraghi F et al. **Mesenchymal stromal cells to promote solid organ transplantation tolerance.** Curr Opin Organ Transplant, 2013. 18: 51.
- Budniatzky I et al. **Concise Review: Reprogramming Strategies for Cardiovascular Regenerative Medicine: From Induced Pluripotent Stem Cells to Direct Reprogramming.** Stem Cells Transl Med, 2014.

Selected Hyperlinks:

- **Generic Drug Immunosuppression in Thoracic Transplantation: An ISHLT Educational Advisory:**
https://www.isHLT.org/ContentDocuments/JHLT_July2009_Generic_Concensus_Statement.pdf

V. RESEARCH MODELS, ASSAYS, AND TECHNOLOGIES

Learning Objectives for Research Models and Clinical Assays:

- 1) Review the different pre-clinical animal models in transplantation research;
- 2) Understand the role of animal models to answer specific transplant-related questions;
- 3) Discuss the advantages and disadvantages of pre-clinical animal models;
- 4) Describe major sources of human samples for translational research;
- 5) Understand key lab techniques to measure innate and adaptive immune responses and to monitor transplant recipients;
- 6) Recognize imaging techniques used to analyze organ function, cell survival and lymphocyte trafficking.

1. Pre-clinical models

A. Animal models – the pros and cons

- i. Murine
- ii. Pig
- iii. Primate
- iv. Ex-vivo conditioned organs

B. Diversity in models

- i. Transgenic models
 - a. Green Fluorescence Protein (GFP) models
 - b. Firefly luciferase (fluc) models
 - c. Other
- ii. Knock-out/in models
- iii. Humanized models

D. Key models of rejection in lung and heart Tx

2. Samples for translational and clinical science

A. Human samples

- i. Blood, serum, plasma
- ii. Lung and heart tissue (biopsies)
- iii. Bronchoalveolar lavage (BAL): supernatant vs. cells
- iv. Explanted allografts (autopsy, retransplant)
- v. Explanted thymuses
- vi. Donor or recipient lymph nodes

B. Sample processing to answer specific research questions

- i. Centrifugation
- ii. Filtration

- iii. Preservation agents
- iv. Cryopreservation
- v. Biobanking

3. Key analytical techniques

A. Protein analysis

- i. Flow cytometry
 - a. Cell characterization
 - b. Antibody titres
 - c. Cell surface proteins
 - d. Intracellular proteins
- ii. Multiplex
- iii. Luminex
- iv. ELISA
- v. ELISpot
- vi. Western Blot
- vii. Immunohistochemistry and immunofluorescence
- viii. Proteomics

B. DNA analysis

- i. Genomic PCR
- ii. DNA degradation

C. Gene expression analysis / transcriptomics

- i. Real-Time PCR
- ii. Gene expression arrays (microarrays)
- iii. Single-cell RNA sequencing
- iv. Epigenetics

D. MicroRNA analysis

E. Cellular Functional Assays

- i. MLR
- ii. CTL
- iii. Other

F. Histopathology

- i. Stains: Hematoxylin-Eosin, Masson Trichrome, PAS, EVG, others
- ii. ISHLT grading or rejection

iii. Immunostaining/immunofluorescence

G. Imaging

- i. Echo
- ii. Molecular Imaging
- iii. Bioluminescence imaging (BLI)
- iv. Coronary imaging
- v. Chest imaging
- vi. microCT

H. Novel technologies

4. Novel technologies for improved diagnostics

A. Biomarkers of rejection

B. Molecular microscope

C. Blood gene expression signatures

D. Graft-derived gene expression signatures

E. MicroRNA analysis

F. Circulating donor cell-free DNA

G. Intra-graft immune cell analyses

Selected References:

- Van der Worp HB et al. **Can animal models of disease reliably inform human studies?** Plos Medicine, 2010. 7: e1000245.
- Doyle A et al. **The construction of transgenic and gene knockout/knockin mouse models of human disease.** Transgenic Res, 2012. 21: 327.
- Plenter RJ et al. **Four decades of vascularized heterotopic cardiac transplantation in the mouse.** J Invest Surg, 2013. 26: 223.
- Wehner JR et al. **Immunological challenges of cardiac transplantation: the need for better animal models to answer current clinical questions.** J Clin Immunol, 2009. 29: 722.
- Junraithmayr W et al. **Small animal models of experimental obliterative bronchiolitis.** Am J Respir Cell Mol Biol, 2013. 48: 675.
- Sato M et al. **Translational Research: animal models of obliterative bronchiolitis after lung transplantation.** Am J Transplant, 2009. 9: 1981.
- Bribriesco AC et al. **Experimental models of lung transplantation.** Front Biosci, 2013. 5: 266.
- Baldwin WM et al. **Antibody-mediated rejection: Emergence of animal models to answer clinical questions.** Am J Transplant, 2010. 10: 1135.
- Lederer DJ. **Translational research in lung transplantation: How do we get from mouse to human?** Am J Transplant, 2012. 12: 281.
- Augustine JJ et al. **T-cell immune monitoring by the ELISPOT assay for interferon gamma.** Clin Chim Acta, 2012. 413: 1359.
- Baan et al. **Phospho-specific flow cytometry for pharmacodynamic monitoring of immunosuppressive therapy in transplantation.** Transplantation research, 2012. 1: 20.
- Khatri et al. **Using gene arrays in diagnosis of rejection.** Curr Opin Organ Transplant, 2009. 13: 34.

- Weichenhan et al. **The evolving epigenome**. Hum Mol Gen, 2013. 22: R1.
- Heyn et al. **DNA methylation profiling in the clinic: applications and challenges**. Nat Rev Genetics, 2012. 13: 679.
- Camirand G. **New perspectives in transplantation through intravital microscopy imaging**. Curr Opin Organ Transplant, 2013. 18: 6.
- Kienzl-Wagner K et al. **Proteomics - a blessing or a curse? Application of proteomics technology to transplant medicine**. Transplantation, 2011. 92: 499.
- Kennedy VE et al. **Bronchoalveolar lavage as a tool to predict, diagnose, and understand bronchiolitis obliterans syndrome**. Am J Transplant, 2013. 13: 552.
- Racusen LC. **Immunopathology of organ transplantation**. Springer Semin Immunopathol, 2003. 25: 141.
- Freer G et al. **Intracellular cytokine detection by fluorescence-activated flow cytometry: basic principles and recent advances**. Methods, 2013. 61: 30.
- Greco A et al. **High-resolution positron emission tomograph/computed tomography imaging of the mouse heart**. Exp Physiol, 2013. 98: 645.
- Botnar RM et al. **Cardiovascular magnetic resonance imaging in small animals**. Prog Mol Biol Transl Sci, 2012. 105: 227.
- Ram R et al. **New approaches in small animal echocardiography: imaging the sounds of silence**. Am J Physiol Heart Circ Physiol, 2011. 301: H1765.
- Schambach SJ et al. **Application of micro-CT in small animal imaging**. Methods, 2010. 50: 2.
- Chen DL et al. **Increased T cell glucose uptake reflects acute rejection in lung grafts**. Am J Transplant, 2013. 13: 2540.
- Ordovas-Montanes J, Dwyer DF, Nyquist SK, Buchheit KM, Vukovic M, Deb C, Wadsworth MH 2nd, Hughes TK, Kazer SW, Yoshimoto E, Cahill KN, Bhattacharyya N, Katz HR, Berger B, Laidlaw TM, Boyce JA, Barrett NA, Shalek AK. [Allergic inflammatory memory in human respiratory epithelial progenitor cells](#). Nature. 2018 Aug;560(7720):649-654
- Danger R, Royer PJ, Reboulleau D, Durand E, Loy J, Tissot A, Lacoste P, Roux A, Reynaud-Gaubert M, Gomez C, Kessler R, Mussot S, Dromer C, Brugière O, Mornex JF, Guillemain R, Dahan M, Knoop C, Botturi K, Foureau A, **Pison C**, Koutsokera A, Nicod LP, Brouard S, Magnan A; COLT and SysCLAD Consortia. [Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome](#). Front Immunol. 2018 Jan 11;8:1841.
- Di Francesco A, Fedrigo M, Santovito D, Ntarelli L, Castellani C, De Pascale F, Toscano G, Fraiese A, Feltrin G, Benazzi E, Nocco A, Thiene G, Valente M, Valle G, Schober A, Gerosa G, Angelini A. [MicroRNA signatures in cardiac biopsies and detection of allograft rejection](#). J Heart Lung Transplant. 2018 Jun 30.
- Agbor-Enoh S, Jackson AM, Tunc I, Berry GJ, Cochrane A, Grimm D, Davis A, Shah P, Brown AW, Wang Y, Timofte I, Shah P, Gorham S, Wylie J, Goodwin N, Jang MK, Marishta A, Bhatti K, Fideli U, Yang Y, Luikart H, Cao Z, Pirooznia M, Zhu J, Marboe C, Iacono A, Nathan SD, Orens J, Valentine HA, Khush K. [Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis](#). J Heart Lung Transplant. 2018 Jul;37(7):925-932
- [Keating BJ^{1,2}, Pereira AC³, Snyder M⁴, Piening BD⁴. Applying genomics in heart transplantation. Transpl Int. 2018 Mar;31\(3\):278-290.](#)
- Khatri P, Roedder S, Kimura N, De Vusser K, Morgan AA, Gong Y, Fischbein MP, Robbins RC, Naesens M, Butte AJ, Sarwal MM. [A common rejection module \(CRM\) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation](#). J Exp Med. 2013 Oct 21;210(11):2205-21
- Li L1, Khush K2, Hsieh SC3, Ying L1, Luikart H2, Sigdel T3, Roedder S3, Yang A2, Valentine H2, Sarwal MM3. Identification of common blood gene signatures for the diagnosis of renal and cardiac acute allograft rejection. PLoS One. 2013 Dec 16;8(12):e82153. doi: 10.1371/journal.pone.0082153. eCollection 2013.
- Halloran PF, Potena L, Van Huyen JD, Bruneval P, Leone O, Kim DH, Jouven X, Reeve J, Loupy A. [Building a tissue-based molecular diagnostic system in heart transplant rejection: The heart Molecular Microscope Diagnostic \(MMDx\) System](#). J Heart Lung Transplant. 2017 Nov;36(11):1192-1200
- Verleden SE, Vasilescu DM, Willems S, Ruttens D, Vos R, Vandermeulen E, Hostens J, McDonough JE, Verbeken EK, Verschakelen J, Van Raemdonck DE, Rondelet B, Knoop C, Decramer M, Cooper J, Hogg JC, Verleden GM, Vanaudenaerde BM. [The site and nature of airway obstruction after lung transplantation](#). Am J Respir Crit Care Med. 2014 Feb 1;189(3):292-300

Selected Hyperlinks:

Web pages:

- **The use of animal models to study genetic disease:** <http://www.nature.com/scitable/topicpage/the-use-of-animal-models-in-studying-855>
- **Transgenic mouse models of human disease:** <http://labs.medicine.ucsf.edu/chrislau/GFP.html>
- **What is PCR:** <http://www.genome.gov/10000207>
- **Guidelines for optimizing PCR – DNA analysis:** <http://www.agctsequencing.com/Articles/PCROptimize1.pdf>
- **Real-time PCR tutorial:** <http://pathmicro.med.sc.edu/pcr/realtime-home.htm>
- **ELISA:** <http://www.bio.davidson.edu/genomics/method/ELISA.html>
- **Western blotting:** <http://www.piercenet.com/method/overview-western-blotting>

Videos:

- **DNA microarrays:** <http://www.youtube.com/watch?v=VNstHmNjKhM>
- **DNA microarrays:** <http://www.youtube.com/watch?v=9U-9mlOzoZ8>
- **Epigenetics overview:** http://www.youtube.com/watch?v=Tj_6DcUTRnM
- **Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation:** <http://www.jove.com/video/3947/development-obliterative-bronchiolitis-murine-model-orthotopic-lung>